Management of rheumatoid arthritis: The historical context

Journal of Rheumatology

Volumn 28, Issue 6, 2001, Pages 1431-1452

  Moreland, L W ^a   Russell, A S ^a   Paulus, H E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biological agents; Disease modifying antirheumatic drugs; Nonsteroidal antiinflammatory drugs; Rheumatoid arthritis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AUROTHIOGLUCOSE; AZATHIOPRINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DICLOFENAC; ETODOLAC; GOLD; IBUPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; METHOTREXATE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PENICILLAMINE; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SALAZOSULFAPYRIDINE; SALICIN; SALICYLATE SODIUM; SULINDAC; TOLMETIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HISTORY OF MEDICINE; HUMAN; INFLAMMATION; LIVER TOXICITY; PHYSICAL DISABILITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS;

EID: 0034982318     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (238)

1. Questionnaire, walking time, and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis
2. Measures of activity and damage in rheumatoid arthritis depiction of changes and prediction of mortality over 5 years
3. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over 15 years
4. Mortality predictors among 263 patients with rheumatoid arthritis
5. Treatment with leflunomide slows radiographic progression of RA. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis
6. Infliximab and methotrexate in the treatment of rheumatoid arthritis
7. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
8. The early history of antirheumatic drugs
9. Salicylates in rheumatic fever: An attempt to assess their value
10. Prognosis in Still's disease
11. Nonsteroidal antirheumatic drugs
12. Inhibition of prostaglandin synthesis as the mechanism of action for aspirin-like drugs
13. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
14. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. II
15. Basic biology and clinical applications of specific cyclooxygenase-2 inhibitors
16. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
17. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors
18. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
19. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs
20. Rheumatoid arthritis and its treatment by gold salts
21. Gold therapy in rheumatoid arthritis
22. Gold therapy in rheumatoid arthritis. Report of a multicenter controlled trial
23. The influence of chrysotherapy on serum proteins and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers
24. Fall in immune complex levels during gold treatment of rheumatoid arthritis
25. Gold salts in the treatment of rheumatoid arthritis: A double-blind study
26. Clinical responses during gold therapy for rheumatoid arthritis: Changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities
27. Gold therapy in early rheumatoid arthritis
28. Chrysotherapy: A prospective study
29. Long-term chrysotherapy in rheumatoid arthritis
30. Termination of treatment with gold sodium thiomalate in rheumatoid arthritis
31. Analysis of treatment terminations with gold and anti-malarial compounds in rheumatoid arthritis
32. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis
33. Antimalarial agents and lupus
34. A controlled study of chloroquine as an antirheumatic agent
35. Chloroquine in rheumatoid arthritis: A double blindfold trial of treatment for one year
36. Chloroquine in rheumatoid arthritis
37. Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis
38. Hydroxychloroquine in treatment of rheumatoid arthritis
39. Hydroxychloroquine in rheumatoid arthritis: A six-month, double-blind trial
40. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study
41. Dosage of antimalarial drugs for children with juvenile RA
42. Hydroxychloroquine compared with placebo in rheumatoid arthritis
43. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis
44. Ocular changes induced by long-term hydroxychloroquine therapy
45. Delayed onset of chloroquine retinopathy
46. Ocular safety of hydroxychloroquine
47. Ocular damage in chloroquine retinopathy
48. Ocular toxicity of antimalarials in dermatology: A survey of current practice
49. Long-term course of chloroquine retinopathy after cessation of medication
50. Ophthalmologic safety of long-term hydroxychloroqume treatment
51. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity
52. Chloroquine neuromyopathy
53. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy
54. Chloroquine neuromyopathy
55. Peripheral neuropathy following chloroquine therapy
56. Bone marrow depression after drug therapy of SLE and rheumatic diseases
57. Agranulocytosis following treatment with hydroxychloroquine
58. Agranulocytosis and hydroxychloroquine
59. Antigen-presenting function of the macrophages
60. Inhibition of DNA and RNA polymerase reactions by chloroquine
61. 2 inhibitors, mepacrine and chloroquine
62. Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release
63. Immunosuppression potentials of anti-malarials
64. Chloroquine-induced inhibition of the production of TNF, but not IL-6, is affected by disruption of iron metabolism
65. Quinacrine inhibits the primary but not secondary proliferative response of human cytotoxic T cells to allogeneic non T-cell antigens
66. Penicillamine: A characteristic degradation product of penicillin
67. Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor
68. Trial comparing D-penicillamine in rheumatoid arthritis: Preliminary report
69. Trial comparing azathioprine and penicillamine in treatment of rheumatoid arthritis
70. Synthetic (D(-) penicillamine in rheumatoid arthritis
71. The technique of penicillamine administration in rheumatoid arthritis
72. D-penicillamine
73. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis
74. Azathioprine in rheumatoid arthritis. A double-blind, cross-over study
75. Azathioprine in rheumatoid arthritis: A double-blind study comparing full dose to half dose
76. Azathioprine in rheumatoid arthritis. A long-term follow-up study
77. Azathioprine in the treatment of chronic polyarthritis: Long-term results and adverse effects in 25 patients
78. Long-term azathioprine in rheumatoid arthritis: A double-blind study
79. Practical results of treatment with disease-modifying antirheumatoid drugs
80. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide
81. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide
82. Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse
83. Cyclophosphamide-sensitive T-lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T-lymphocytes
84. Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors
85. Comparison of azathioprine, cyclophosphamide and gold in treatment of rheumatoid arthritis
86. Trial comparing azathioprine and penicillamine in treatment of rheumatoid arthritis
87. Toxic effects of azathioprine in rheumatoid arthritis: A national postmarketing perspective
88. Azathioprine vs. D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold
89. Treatment of rheumatoid arthritis with nitrogen mustard. Preliminary report
90. Long-term cyclophosphamide therapy in rheumatoid arthritis
91. Cyclophosphamide therapy for rheumatoid arthritis
92. Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis
93. Controlled trials of cyclophosphamide in rheumatoid arthritis
94. A controlled trial of cyclophosphamide in rheumatoid arthritis
95. Salasopyrin in the treatment of rheumatoid arthritis
96. Salazopyrin in rheumatoid arthritis
97. Sulphasalazine in rheumatoid arthritis
98. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial
99. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis
100. Sulfasalazine in rheumatoid arthritis: A double-blind, placebo-controlled trial
101. Sulphasalazine: A safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate
102. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis
103. Methotrexate therapy in psoriatic arthritis. Double-blind study on 21 patients
104. Efficacy of low-dose methotrexate in rheumatoid arthritis
105. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study
106. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
107. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
108. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety
109. The effects of methotrexate on the production and activity of interleukin-1
110. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: Effects of a single dose methotrexate
111. Interleukin-6 and soluble 1L-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate
112. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate
113. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate
114. Phospholipase A2 activity in peripheral blood cells of rheumatoid arthritis patients treated with methotrexate: A preliminary study
115. Immunologic studies of rheumatoid arthritis patients treated with methotrexate
116. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expressions
117. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate
118. Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety
119. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
120. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months
121. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
122. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months
123. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis
124. Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice
125. Methotrexate therapy in rheumatoid arthritis: 15 years experience
126. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update
127. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment
128. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis
129. Use of short-term efficacy/toxicity tradeoffs to select second-line drags in rheumatoid arthritis. A metaanalysis of published clinical trials
130. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the Cooperative Systemic Studies of the Rheumatic Diseases Program randomized clinical trial of methotrexate, auranofin, or a combination of the two
131. Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study
132. Methotrexate treatment of rheumatoid arthritis: Effects on radiographic progression
133. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
134. Methotrexate in rheumatoid arthritis. An update
135. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid arthritis
136. Hepatic methotrexate content and progression of hepatic fibrosis: Preliminary findings
137. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples
138. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate
139. Methotrexate-associated hepatotoxicity: Retrospective analysis of 210 patients with rheumatoid arthritis
140. Liver biopsy and methotrexate use: See no evil? Methotrexate and histologic abnormalities: A meta-analysis
141. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates
142. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis
143. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity
144. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate
145. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder
146. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis
147. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: A case report and review of the literature
148. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis
149. Severe reversible interstitial pneumonitis induced by low dose methotrexate
150. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis
151. Pulmonary disease complicating intermittent therapy with methotrexate
152. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis
153. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomized, multicenter trial
154. Disease modification in rheumatoid arthritis with leflunomide
155. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and lefiunomide in patients with active rheumatoid arthritis
156. FK-506, and rapamycin. Pharmacologic probes of lymphocyte signal transduction
157. Threedimensional structure and actions of immunosuppressants and their immunophilins
158. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription
159. Inhibition of T and B lymphocyte proliferation by rapamycin
160. Die Therapie der chronischen polyarthritis mit Cyclosporin A, einen neuen immune-suppressivum
161. Cyclosporin in rheumatoid arthritis. Open trials with different dosages
162. Cyclosporin A in rheumatoid arthritis. Preliminary clinical results of an open trial
163. Long-term treatment of rheumatoid arthritis with cyclosporin
164. Cyclosporine A treatment of refractory rheumatoid arthritis
165. Low dose cyclosporin in rheumatoid arthritis. A pilot study
166. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis
167. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis. A preliminary report
168. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis. A randomized, double-blind multicenter study
169. Cyclosporine vs azathioprine in the treatment of rheumatoid arthritis, a controlled double blind study
170. Cyclosporine as a disease modifier in rheumatoid arthritis
171. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis
172. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study
173. Cyclosporin in rheumatoid arthritis. A double blind, placebo controlled study in 52 patients
174. Cyclosporin treatment for rheumatoid arthritis. A placebo controlled, double-blind, multicenter study
175. Combination drug therapy of seropositive rheumatoid arthritis
176. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)
177. Combination therapy in rheumatoid arthritis: Updated systematic review
178. Combination DMARD therapy for rheumatoid arthritis: Apparent universal acceptance
179. Use of second line "disease-modifying" anti-rheumatic drugs within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under care of 142 US rheumatologists: An inception cohort study
180. Remission in rheumatoid arthritis
181. Effect of gold on progression of erosions in rheumatoid arthritis: Better results with early treatment
182. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
183. A three year comparative multicenter study of auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis
184. The effectiveness of early treatment with "second-line" antirheumatic drugs: A randomized controlled trial
185. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: Results of a 48-week multi-center study comparing low-dose cyclosporine with placebo
186. Radiographic progression in rheumatoid arthritis: Results of 3 comparative trials
187. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A
188. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
189. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone
190. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study
191. Combination drug therapy of seropositive rheumatoid arthritis
192. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial
193. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial
194. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: A randomised double blind trial
195. Combination therapy in rheumatoid arthritis - No benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy
196. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
197. Inhibition of tumor necrosis factor for rheumatoid arthritis
198. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
199. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
200. Etanercept therapy in rheumatoid arthritis
201. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients in rheumatoid arthritis receiving methotrexate
202. Safety and efficacy of tumor necrosis factor receptor p75 fusion protein (TNFR:Fc, Enbrel™) in DMARD refractory rheumatoid arthritis
203. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
204. The American College of Rheumatology definition of improvement in rheumatoid arthritis
205. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-alpha (cA2) versus placebo in rheumatoid arthritis
206. Repeated therapy with monoclonal antibody to tumor necrosis factor-alpha (cA2) in patients with rheumatoid arthritis
207. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
208. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-alpha
209. Medical and social aspects of the treatment of rheumatoid arthritis with special reference to factors affecting prognosis
210. A controlled trial of the effect of complete immobilization of the joint in rheumatoid arthritis
211. Drug treatment of rheumatoid arthritis
212. Clinical trials of cortisone, ACTH and other therapeutic measures in chronic rheumatic diseases. A comparison of prednisolone with aspirin and other analgesics in the treatment of rheumatoid arthritis
213. Earlier intervention with second line therapies
214. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
215. Low dose prednisone therapy retards radiographically detectable destruction in early rheumatoid arthritis
216. Progression of radiographic joint erosion during low-dose corticosteroid treatment of rheumatoid arthritis
217. The effect of elective total hip replacement on health related quality of life
218. Functional status predicts mortality in a community based rheumatoid arthritis population
219. Long term drug therapy for RA in 7 rheumatology private practices: 2nd line drugs and prednisone
220. 50 years of antirheumatic therapy: The prognosis of rheumatoid arthritis
221. Remodelling the pyramid: A concept whose time has come
222. Challenging the therapeutic pyramid: A new look at treatment strategies for rheumatoid arthritis
223. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians
224. Re-evaluating the therapeutic approach to rheumatoid arthritis: The "saw tooth" strategy
225. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
226. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
227. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
228. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
229. Variations and trends in the prescription of initial 2nd line therapy for patients with RA
230. Antirheumatic drugs: A proposed new classification
231. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine in early rheumatoid arthritis
232. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy
233. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate